RED BANK, N.J. -- Ansell Healthcare Products Inc. introduces its new Ansell Performance polyisoprene (PI) surgical glove. The latex-free and powder-free glove features many of the benefits associated with natural rubber latex products, including superior barrier protection, and exceptional dexterity and sensitivity. It is intended for general-purpose use.
Polyisoprene is the material most similar to latex available in the glove
market today. Ansell Performance PI gloves offer the high level of puncture resistance, excellent elasticity, strength and durability associated with latex gloves, without the risks of latex allergies. The gloves also have a lightly textured finish for superior grip and
exceptional touch sensitivity, and are color-coded green to be easily
distinguished as latex-free.
The environmental impact of disposal is an important issue in the medical supply industry. Polyisoprene produces only water and carbon dioxide upon incineration, making it more environmentally friendly than most synthetics, including neoprene and vinyl, which release hydrochloric acid.
The Ansell Performance PI general-purpose surgical glove is the first offering in the company's new polyisoprene product line. They will be adding additional polyisoprene gloves to the line in the future, including a heavier, thicker glove for orthopedic surgery and a delicate, thinner glove for cardiothoracic and opthalmic diagnostic microsurgeries.
Ansell Healthcare Products Inc. is a global leader in healthcare barrier protective products.
Source: Ansell Healthcare Products Inc.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.
The Neglected Tropical Diseases You’ve Never Heard Of
February 27th 2024The 20 conditions, known as neglected tropical diseases (NTDs), are estimated to affect more than 1 billion people, yet many individuals have never heard of them. Heather Saunders, MPH, RN, CIC, discusses 5 of them and what is being done to prevent their spread.